Target ALS, ADDF Team Up to Fund Biomarker Research

Target ALS, ADDF Team Up to Fund Biomarker Research

315102

Target ALS, ADDF Team Up to Fund Biomarker Research

A new partnership between Target ALS and the Alzheimer’s Drug Discovery Foundation (ADDF) will help facilitate biomarker research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and frontotemporal dementia (FTD). Identifying and validating appropriate biomarkers can help clinicians diagnose these diseases earlier, reliably track their progression, and assess the effects of new therapies, allowing for more efficient clinical trials. The collaboration includes financial support from the ADDF’s Diagnostics Accelerator — a worldwide research…

You must be logged in to read/download the full post.